FindTrial
Sign In

Immune checkpoint inhibitors versus ramucirumab plus docetaxel for refractory or relapsed advanced non-small cell lung cancer: A systematic review and network meta-analysis of phase 3 randomized clinical trials.

Immune checkpoint inhibitors versus ramucirumab plus docetaxel for refractory or relapsed advanced non-small cell lung cancer: A systematic review and network meta-analysis of phase 3 randomized clinical trials. - Immune checkpoint inhibitors versus ramucirumab plusdocetaxel for refractory or relapsed advanced NSCLC

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000041086
Enrollment
500
Registered
2020-07-20
Start date
2020-07-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Sponsors

Showa University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: refractory or relapsed advanced non-small lung cancer performance status of 0 or 1

Exclusion criteria

Exclusion criteria: (The article search were restricted to those published in the English language)

Design outcomes

Primary

MeasureTime frame
Overall survival and Grade 3-5 adverse events—

Secondary

MeasureTime frame
progression free survival—

Countries

Japan

Contacts

Public ContactKoichi Ando

Ando Department of Medicine, Division of Respiratory Medicine and Allergology,

koichi-a@med.showa-u.ac.jp+81-3-3784-8532

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026